9 Meters, Jounce, and Merck updates

Proof-of-concept data and expectations on anti-ILT4/anti-ILT3 programs and more!

9 Meters Biopharma ($NMTR) Long Awaited Data is Disappointingly Vague

NMTR reported data on short bowel syndrome (SBS), and it was vague, even though the company has delayed this data readout by 6 months.

What Was Expected

Phase 2 was initially expected to be reported by the end of 2021. The vurolenatide (formerly called NM-002) study enrolled 22 patients …